ADCS/NIA PROTOCOL ACD-016: HIGH DOSE SUPPLEMENTS AND ALZHEIMER'S DISEASE

ADCS/NIA 方案 ACD-016：高剂量补充剂和阿尔茨海默病

• 批准号: 7376846
• 负责人: MAREK-MARSEL M MESULAM
• 金额: $ 1.18万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376846
• 关键词: ADCS; NIA; PROTOCOL; ACD; 016

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Blood levels of homocysteine, a sulfur amino acid, have been demonstrated to be elevated in Alzheimer's Disease (AD). Hyperhomocysteinemia may contribute to disease pathophysiology by vascular and direct neurotoxic mechanisms. Homocysteine levels can be reduced by administration of high dose supplements of folic acid and vitamins B6 and B12. Four drugs have been approved by the FDA for the treatment of AD, all cholinesterase inhibitors. By boosting brain levels of the neurotransmitter acetylcholine, they improve cognitive function. They are considered to be symptomatic treatments; they have not been proven to slow the progression of the disease. This proposal is based on the hypothesis that homocysteine reduction will have a disease-modifying effect in AD. This trial is an eighteen month randomized trial of 400 patients at 40 sites.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。血液中同型半胱氨酸（一种含硫氨基酸）水平已被证明在阿尔茨海默病（AD）中升高。高同型半胱氨酸血症可能通过血管和直接神经毒性机制促进疾病病理生理。高剂量补充叶酸和维生素B6和B12可以降低同型半胱氨酸水平。FDA已经批准了四种治疗阿尔茨海默病的药物，都是胆碱酯酶抑制剂。通过提高大脑中神经递质乙酰胆碱的水平，它们可以改善认知功能。它们被认为是对症治疗；尚未证明它们能减缓疾病的进展。这一建议是基于同型半胱氨酸减少将对阿尔茨海默病有疾病改善作用的假设。这项试验是一项为期18个月的随机试验，在40个地点的400名患者中进行。